In our lead-in episode for #ILC2021, Roger Green conducts interviews with three leaders, each with a unique perspective on what they value about this week’s Congress. Incoming EASL Secretary General Prof. Thomas Berg discusses his view on the various ways the Congress will enrich knowledge and interaction in the global Fatty Liver community. Global Liver Institute President and CEO Donna Cryer shares the many ways that ILC has made patients and advocates feel they are welcome at the Congress and capable of making a contribution. Finally, Genfit Head of Global Diagnostics Suneil Hosmane identifies several areas of knowledge that he considers in assessing commercial opportunities. This can serve as a helpful introduction to the Congress or an opportunity to process what you have just seen and learned.

TOPICS: Akero Therapeutics, cirrhosis, Diabetes, EASL, efruxifermin, FibroScan, Genfit, Global Liver Institute, inventiva, lanifibranor, Lean NASH, Madrigal, NAFLD, NASH, non-invasive liver testing, Obesity, Patient Advocacy, Patient Reported Outcomes, Patient-Reported Outcomes, Perspectum Diagnostics, resmetirom, Digital ILC 2021

Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast